Choon-Peng Ng, ImmunoScape CEO

TCR up­start gets fresh fund­ing as it looks to charge to­ward the clin­ic

While sev­er­al com­pa­nies have been find­ing suc­cess in the TCR-T cell ther­a­py space — with In­tel­lia hav­ing its treat­ment ac­cept­ed by the FDA last year — an­oth­er com­pa­ny is us­ing ma­chine learn­ing to get in on the ac­tion and find a can­di­date to bring to­ward the clin­ic.

Im­munoScape, a biotech based in Sin­ga­pore and Cal­i­for­nia, has raised $14 mil­lion in a fresh round of fi­nanc­ing. The com­pa­ny it­self was found­ed in 2016 as a spin­out from the Sin­ga­pore-based Agency for Sci­ence, Tech­nol­o­gy and Re­search, set­ting up its US op­er­a­tions in San Diego in 2020.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.